Eli Lilly and Company (VIE:LLYC)
Austria · Delayed Price · Currency is EUR | Market Cap | 927.10B +51.5% |
| Revenue (ttm) | 62.66B +47.4% |
| Net Income | 21.92B +127.6% |
| EPS | 24.42 +129.1% |
| Shares Out | n/a |
| PE Ratio | 42.29 |
| Forward PE | 32.12 |
| Dividend | 5.52 (0.53%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 48 |
| Open | 1,008.80 |
| Previous Close | 998.20 |
| Day's Range | 1,004.00 - 1,036.20 |
| 52-Week Range | 539.10 - 1,085.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has...
Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Madison Muller has more on "Bloomberg Open Inte...
Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion
Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.
Eli Lilly to acquire AtaiBeckley for $6.75 per share plus $2.50 per share CVR
Eli Lilly (LLY) announced a definitive agreement for Lilly to acquire AtaiBeckley (ATAI). AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage program...
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly said on Thursday it would acquire psychedelic drug developer AtaiBeckley for up to $3.8 billion, entering the race to develop psychedelic treatments for depression and other ment...
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. AtaiBeckley is developing several psychedelics for mental health conditions.
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging...
This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks
Eli Lilly is in talks to buy a psychedelic drugmaker at a premium, according to a report.
Eli Lilly in talks to acquire AtaiBeckley, Bloomberg reports
Eli Lilly (LLY) is in discussions to acquire AtaiBeckley (ATAI) and a formal takeover could take place as soon as this week, Bloomberg’s Eyk Henning and Madison Muller report, citing…
Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
Eli Lilly is in talks to acquire psychedelic drugmaker AtaiBeckley , and a deal could be announced as soon as this week, Bloomberg News reported on Wednesday, citing people familiar with th...
Eli Lilly close to acquisition of AtaiBeckley, Bloomberg reports
18:48 EDT Eli Lilly (LLY) close to acquisition of AtaiBeckley (ATAI), Bloomberg reports
VivoSim receives $5M milestone payment from Eli Lilly
VivoSim (VIVS) announced that it has received a $5M payment from Eli Lilly (LLY). In association with its former inflammatory bowel disease drug program developed previously and sold outright to…
Eli Lilly price target raised to $1,600 from $1,500 at Citi
Citi raised the firm’s price target on Eli Lilly (LLY) to $1,600 from $1,500 and keeps a Buy rating on the shares. The firm adjusted targets in the biopharma group…
It's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.
The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.
Study flags need to monitor frailty risks with GLP-1 drugs for older adults
Potential signs of frailty in older adults taking Eli Lilly's GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes, according to a large study that underscores concerns a...
Retevmo granted FDA traditional approval for RET fusion-positive solid tumors
The Food and Drug Administration granted traditional approval to selpercatinib or Retevmo, from Eli Lilly (LLY), for adult and pediatric patients two years of age and older with locally advanced…
Is Lilly Stock On Track To Hit $2,090?
This article was written by Doug Nathman, with research by his team at Trefis.
Eli Lilly price target raised to $1,385 from $1,300 at Bernstein
Bernstein raised the firm’s price target on Eli Lilly (LLY) to $1,385 from $1,300 and keeps an Outperform rating on the shares. Eli Lilly shares have performed strongly in Q2…
Eli Lilly price target raised to $1,425 from $1,250 at UBS
UBS raised the firm’s price target on Eli Lilly (LLY) to $1,425 from $1,250 and keeps a Buy rating on the shares.
Eli Lilly price target raised to $1,273 from $1,235 at Guggenheim
Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $1,273 from $1,235 and keeps a Buy rating on the shares after updating the firm’s model ahead of Q2…
Eli Lilly price target raised to $1,334 from $1,251 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,334 from $1,251 and keeps a Buy rating on the shares. Second quarter results are expected to highlight stronger…
Eli Lilly price target raised to $1,370 from $1,281 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,370 from $1,281 and keeps a Buy rating on the shares ahead of its Q2 results. The quarter could…
Eli Lilly to presents abstracts at 2026 AAIC on Kisunla trials
Eli Lilly (LLY) announced it will present 16 abstracts at the 2026 Alzheimer’s Association International Conference, AAIC,, July 12-15 in London. Three oral presentations anchor the scientific program...
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood te...
Strong LLY News Boosts Active Healthcare ETF GDOC
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.